Is Kilitch Drugs (India) Ltd (KILITCH) a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Kilitch Drugs (India) Ltd is a below average quality company .

Is Kilitch Drugs (India) Ltd (KILITCH) undervalued or overvalued?

The key valuation ratios of Kilitch Drugs (India) Ltd's currently when compared to its past seem to suggest it is in the Fair zone .

What is Kilitch Drugs (India) Ltd (KILITCH) share price return in the past 10 years?

Kilitch Drugs (India) Ltd share price has appreciated 22% annually (CAGR) over the past ten years.

Is Kilitch Drugs (India) Ltd (KILITCH) a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Kilitch Drugs (India) Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

What is the share price of Kilitch Drugs (India) Ltd (KILITCH)?

Company share prices are keep on changing according to the market conditions. The current trading price of Kilitch Drugs (India) Ltd (KILITCH) on 17-Apr-2026 16:59:59 at 16:59 is 135.10.

What is the P/E ratio of Kilitch Drugs (India)?

The latest standalone P/E ratio of Kilitch Drugs (India) as of 17-Apr-2026 is 15.87.

What is the P/B ratio of Kilitch Drugs (India) Ltd (KILITCH)?

The latest standalone P/B ratio of Kilitch Drugs (India) Ltd (KILITCH) as of 17-Apr-2026 is 1.40.

What is the 52-week high and low of Kilitch Drugs (India) Ltd (KILITCH)?

The 52-week high of Kilitch Drugs (India) Ltd (KILITCH) is Rs. 245.00 and the 52-week low is Rs. 121.10.

Kilitch Drugs (India) Ltd (KILITCH) Share Analysis – Quality, Pipeline & Valuation Zone & DeciZen Rating

Name: Kilitch Drugs (India) Ltd (KILITCH)
Brand: Kilitch Drugs (India)

Kilitch Drugs (India) Ltd (KILITCH) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

Kilitch Drugs (India) Ltd (KILITCH)

BSE: 524500 NSE: KILITCH

Key Metrics

Market Cap

₹472 Cr.

P/E Ratio

15.87

Price to Book (P/B)

1.40

Price to Sales (P/S)

2.73

EV/EBITDA

12.49

Return on Capital Employed (ROCE)

15.49%

Current Price

₹135.1

Return on Equity (ROE)

13.11%

Return on Assets (ROA)

9.73%

Operating Profit Margin

17.1%

Net Profit Margin

17.16%

Gross Profit Margin

23.4%

Book Value per Share

₹96.8

Sales Growth (YoY)

37.99%

Sales Growth (3 Years)

19.97%

Operating Profit Growth (1 Year)

52.4%

Operating Profit Growth (3 Years)

40.88%

Net Profit Growth (1 Year)

77.35%

52-Week Low / High

₹121 / 245

Net Profit Growth (3 Years)

43.57%

Dividend Yield

0.00%

Promoter Holding

63.77%

Pledged shares (%)
of Promoter's holding (%)

0.00%

Check Before You Invest

Q.1 Revenue growth of Kilitch Drugs (India) Ltd?

Kilitch Drugs (India) Ltd revenue growth is 38% for FY-2025 , which is above its 5 year CAGR of 24.5% , indicating faster growth.

Q.1 Promoter shareholding and pledge status of Kilitch Drugs (India) Ltd?

Promoters hold 63.77% of the Kilitch Drugs (India) Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Revenue growth of Kilitch Drugs (India) Ltd vs industry peers?

Kilitch Drugs (India) Ltd revenue CAGR is 24.47% , compared to the industry median CAGR of 5.54% , indicating faster growth and gaining its market share.

Q.1 Which industry/sub-sector does Kilitch Drugs (India) Ltd belong to?

Kilitch Drugs (India) Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.

Q.1 Stock return of Kilitch Drugs (India) Ltd over the last decade?

Over the last 9 year(s), the stock has delivered a CAGR of 21.9% based on the current price.

DeciZen - make an informed investing decision on Kilitch Drugs(India)

Based on:

Data

Overall Rating ⓘ
Login to view analysis. M-Cap below 500cr. High Risk from low Liquidity

1. Quality

2. Valuation

3. Price Trend

Kilitch Drugs (India) stock performance

Key Ratios

Is Kilitch Drugs (India) Ltd an attractive stock to invest in?

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	-2%	-0.3%	6%	13.8%	3.8%	4.9%	7.8%	9.9%	10.8%	15.5%	-
Value Creation Index ⓘ	-1.2	-1.0	-0.6	0.0	-0.7	-0.7	-0.4	-0.3	-0.2	0.1	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	21	28.1	50.5	96.4	60.8	70	105	118	132	182	173
Sales YoY Gr.	-	33.9%	79.3%	91.1%	-37%	15.2%	50.2%	12%	11.7%	38%	-
Adj EPS ⓘ	-0.8	0.1	1.8	4.1	0.7	1.5	2.9	4.4	4.6	7.5	8.5
YoY Gr.	-	NA	1358.3%	136.6%	-84.1%	121.2%	101.4%	49%	4.8%	63.2%	-
BVPS (₹) ⓘ	43.1	43.5	45.4	47.8	47.7	51.3	55	59.8	67.7	76.9	96.8
Adj Net Profit ⓘ	-2.3	0.3	4.9	13	2.1	4.6	9.4	13.9	15.1	24.6	30
Cash Flow from Ops. ⓘ	18	0.6	-1.3	7.4	7.3	6.1	5.2	6.1	-2.6	15.2	-
Debt/CF from Ops. ⓘ	0	1.1	-0.6	1.3	1.7	2.4	3.9	3.6	-12.1	3.2	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	27.1%	24.5%	20%	38%
Adj EPS ⓘ	NA	62.6%	36.6%	63.2%
BVPSⓘ	6.6%	10%	11.8%	13.5%
Share Price	22%	21.9%	20.4%	-20.5%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	-1.9	0.3	3.9	9.2	1.4	3	5.5	7.5	7.2	10.4	9.8
Op. Profit Mgn % ⓘ	-15	0.5	11.1	17	1.9	7.6	11.3	14.7	15.5	17.1	15.5
Net Profit Mgn % ⓘ	-10.7	1.2	9.8	13.5	3.4	6.6	8.9	11.8	11.5	13.6	17.2
Debt to Equity ⓘ	0	0	0	0.1	0.1	0.1	0.1	0.1	0.1	0.2	-
Working Cap Days ⓘ	536	280	193	173	373	364	299	314	319	285	180
Cash Conv. Cycle ⓘ	244	163	86	64	107	59	39	32	55	58	104

Recent Performance Summary

Latest Financials

	Standalone	Consolidated
TTM EPS (₹)	8.5	7.5
TTM Sales (₹ Cr.)	173	207
BVPS (₹) ⓘ	96.8	82.2
Reserves (₹ Cr.) ⓘ	303	252
P/BV ⓘ	1.40	1.64
PE ⓘ	15.87	18.13

From the Market
52 Week Low / High (₹)	121.10 / 245.00
All Time Low / High (₹)	0.37 / 245.00
Market Cap (₹ Cr.)	472
Equity (₹ Cr.)	35
Face Value (₹)	10
Industry PE ⓘ	42.1

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Kilitch Drugs(India) - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Key Ratios

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	21	28	50	96	61	70	105	118	132	182
Operating Expenses ⓘ +	25	29	45	81	60	65	94	100	111	150
Manufacturing Costs	4	4	3	4	5	5	8	8	7	8
Material Costs	9	11	26	53	36	39	60	58	66	92
Employee Cost	3	3	4	5	6	5	6	7	8	10
Other Costs ⓘ	9	10	11	18	13	15	20	27	30	40
Operating Profit ⓘ	-4	-1	6	16	1	5	11	17	20	31
Operating Profit Margin (%)	-16.9%	-2.0%	11.1%	16.2%	1.9%	7.6%	10.6%	14.7%	15.5%	17.1%
Other Income ⓘ +	3	2	3	6	6	4	5	5	6	14
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	0
Interest ⓘ	0	0	0	1	1	1	1	1	2	2
Depreciation ⓘ	2	1	1	1	1	1	1	1	1	2
Profit Before Tax ⓘ	-2	-0	7	20	5	8	14	19	23	41
Tax ⓘ	-0	-0	1	5	1	1	3	4	6	10
Profit After Tax	-2	-0	6	15	4	6	11	16	18	31
PAT Margin (%)	-9.8%	-0.1%	12.3%	15.3%	7.3%	8.8%	10.0%	13.3%	13.4%	17.2%
Adjusted EPS (₹)	-0.8	-0.0	2.2	4.7	1.4	1.9	3.3	4.9	5.4	9.5
Dividend Payout Ratio (%)	0%	0%	11%	5%	0%	0%	0%	0%	0%	0%

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	117	118	127	150	150	163	175	191	223	253
Share Capital ⓘ	13	13	14	15	15	15	16	16	16	16
Reserves ⓘ	103	104	114	135	135	147	160	175	206	237
Debt +	0	1	1	9	13	15	20	22	31	49
Long Term Debt	0	0	0	0	0	0	0	0	0	28
Short Term Debt	0	1	1	9	13	15	20	22	31	21
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	4	6	8	5	8	14	28	29	26	47
Others Liabilities ⓘ	4	4	8	6	2	4	8	9	5	6
Total Liabilities ⓘ	125	128	144	171	173	195	231	250	285	355
Fixed Assets
Net Fixed Assets ⓘ +	8	8	7	8	8	7	14	15	16	20
Gross Block	23	24	25	26	27	28	36	38	40	46
Accumulated Depreciation	15	16	17	18	20	21	22	23	24	26
CWIP ⓘ	0	0	0	0	0	0	0	1	6	47
Investments ⓘ	92	96	101	100	98	107	117	110	121	121
Inventories	3	3	3	5	6	4	5	2	4	15
Trade Receivables	16	15	21	23	17	23	41	53	62	83
Cash Equivalents	3	2	4	4	3	6	2	18	19	7
Others Assets ⓘ	3	4	9	32	42	49	50	51	58	61
Total Assets ⓘ	125	128	144	171	173	195	231	250	285	355

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	18	1	-1	7	7	6	5	6	-3	15
PBT ⓘ	-2	-0	7	20	5	8	14	19	23	41
Adjustment ⓘ	1	1	-1	-3	-4	-0	0	2	2	-6
Changes in Working Capital ⓘ	20	0	-7	-5	9	0	-6	-11	-21	-11
Tax Paid ⓘ	-0	0	-0	-4	-2	-1	-3	-4	-7	-8
Cash Flow From Investing Activity ⓘ +	-20	-1	-2	-22	-10	-5	-16	6	-9	-41
Capex	0	-1	-1	-2	-1	-0	-8	-4	-7	-47
Net Investments	-20	0	-2	2	0	-0	-7	7	-2	5
Others ⓘ	-1	-0	1	-22	-9	-5	-1	3	-1	1
Cash Flow From Financing Activity ⓘ +	-0	-0	6	15	1	2	8	3	11	16
Net Proceeds from Shares ⓘ	0	0	3	0	0	0	0	0	4	0
Net Proceeds from Borrowing ⓘ	0	0	0	0	0	0	0	0	0	28
Interest Paid ⓘ	0	0	0	0	0	0	-1	-1	-2	-2
Dividend Paid ⓘ	-0	-0	-0	-1	-2	0	0	0	0	0
Others ⓘ	0	0	3	15	3	2	8	4	9	-10
Net Cash Flow ⓘ	-2	-0	2	0	-1	3	-3	15	0	-11

Finance Ratio

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	-1.75	-0.03	5.06	10.65	2.97	3.93	6.23	8.59	8.51	13.11
ROCE (%)	-2.04	-0.26	6.01	13.79	3.79	4.91	7.83	9.9	10.75	15.49
Asset Turnover Ratio	0.17	0.22	0.37	0.61	0.35	0.38	0.49	0.49	0.49	0.57
PAT to CFO Conversion(x)	N/A	N/A	-0.17	0.47	1.75	1	0.45	0.38	-0.17	0.48
Working Capital Days
Receivable Days	252	201	127	83	121	104	112	146	159	146
Inventory Days	43	34	19	14	31	24	15	11	8	19
Payable Days	125	150	94	45	68	100	125	177	152	146

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Kilitch Drugs (India) Ltd FAQs

The current trading price of Kilitch Drugs(India) on 17-Apr-2026 16:59 is ₹135.1.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 16-Apr-2026 the market cap of Kilitch Drugs(India) stood at ₹472.3 Cr

The latest P/E ratio of Kilitch Drugs(India) as of 16-Apr-2026 is 15.87.

The latest P/B ratio of Kilitch Drugs(India) as of 16-Apr-2026 is 1.40.

The 52-week high of Kilitch Drugs(India) is ₹245.0 and the 52-week low is ₹121.1.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Kilitch Drugs(India) is ₹173 ( Cr.) .

About Kilitch Drugs (India) Ltd

Kilitch Drugs is a pharmaceutical company, its services range from manufacturing to marketing a host of formulations in all dosage forms i.e. solid, liquid and parenteral forms. With nearly two decades of creating safe pharmaceutical solutions and the ultimate purpose of making the world a healthier place.

Kilitch is one of the largest manufacturers of antibacterial parenteral formulations. It is also one of the largest producers of sterile liquid formulations in small volumes in India. Kilitch also boasts of 25 years of quality contract manufacturing service to reputed national and multinational pharmaceutical companies. its sound knowledge about the industry has resulted in the growth of the organizations along with them as a leading contract manufacturing company in the country.

Keeping pace with the increasing demand of its clients for contract manufacturing, Kilitch has added 2 dedicated blocks and is in the process of adding another 3 dedicated fully USFDA / UKMHRA compliant manufacturing facility in Paonta Sahib (North India). All its plants are approved by the local as well as World Health Organization (WHO) for GMP standards. Kilitch has 3 manufacturing facilities spread across India.

Kilitch has over 25 years of experience in product development and manufacturing. It offers a wide spectrum of contract services, providing reliable supply, scientific expertise and bottom line results to meet the development, clinical and commercial outsourcing needs. Kilitch has been engaged in successful tie-ups with over 20 leading pharmaceutical companies -- Ranbaxy Laboratories Limited, Sandoz India Limited, Zydus Cadila, Nicholas Piramal India Limited, USV Limited, Merck Limited to name a few.

In 2010 the company listed its Equity Shares at NSE.

DCGI Approval-- The company has received the DCGI approvals for Ceftriaxone+Tazobactam, Ceftriaxone+Salbactam,Cefipime +Tazobactam and awaiting for approval for the following products, Rabeprazole, Ceftazidime+Tazobactam, Cefoperazone+Tazobactam

Product range of the company includes- Carbapenems, Cephalosporins, Beta - Lactam Antibiotics, Steroids & Hormones, Gastrology, Gastrology, NSAIDs, Anti Malarials

Kilitch has signed an agreement with a US-based pharmaceutical company for manufacturing of its generic molecules for the period of 2 year which started in mid 2008 and would like to expand their business thereon.

Clientele: Sandoz, Ranbaxy, Emcure, Nicholas, Ajanta pharma, Zuventas, Zydus Cadilla, USV, Flamingo Pharma and many others.

To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

Build a Stress-Tested Portfolio.

Our Sapphire Advisory uses the ABC Concept to ensure you never have to panic during a market correction.

Core Stocks

STABILITY

Booster Stocks

GROWTH

Amplifier Stocks

ASYMMETRY

● Conflict-Free ● SEBI Registered ● 15Y+ Track Record

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Kilitch Drugs (India) Ltd (KILITCH) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

Kilitch Drugs(India) Share Price